SecBot SecBot

GENB drug pipeline

$12.07
−4.0% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketEstimated at 2-4 years assuming successful completion of the ongoing Phase 3 trials, regulatory filing, and FDA review.

GB-0895 golukibart Updated Nov 14

What to watch

GB-0895 is the lead asset driving essentially all of GENB's valuation. Watch for updates on SOLAIRIA-1 and SOLAIRIA-2 enrollment completion and any disclosed Phase 3 topline timeline, as that will be the next major binary event. Also monitor Tezspire's (tezepelumab) commercial trajectory and label expansion, as it is the direct competitor and its performance sets market expectations for TSLP-targeting therapies. The Zealand Pharma partnership provides non-dilutive cash but is early-stage and adds no near-term revenue.

Bull case
  • GB-0895 is a potentially best-in-class anti-TSLP antibody designed for twice-yearly (every 6 months) subcutaneous dosing versus Tezspire's monthly injections, a significant convenience advantage that could drive adoption and market share in severe asthma.
  • Phase 1 data presented at ERS 2025 showed a single dose produced sustained biomarker effects (reduced eosinophils, FeNO, IL-13, IL-5) for 6 months, supporting the extended dosing interval thesis.
  • Analyst consensus is strongly positive: 11 analysts rate the stock a Buy or Strong Buy (only 1 Hold, no Sells), with a mean price target of $27 (approx 124% upside from the current ~$12).
Bear case
  • GB-0895 faces entrenched competition from Amgen/AstraZeneca's Tezspire (tezepelumab), the first approved anti-TSLP antibody that is already generating sales and expanding into additional indications like eosinophilic esophagitis (EoE) and COPD.
  • Phase 3 trials involve ~1,600 patients across six global regions and are still recruiting (as of Q3 2026), suggesting a topline readout is likely years away; no near-term binary catalyst exists.
  • The company is pre-revenue and burning cash (Q3 2026 net loss of $87.7M, revenue down 56% YoY). Despite $404.2M in cash, ongoing losses require capital discipline and the runway extends only to H1 2028.
● neutral
Impact
PhasePreclinical / Phase 1
Time to marketEarly stage; if Phase 1 begins as projected in mid-2026, a potential approval would be several years away, contingent on successful safety and efficacy data.

GB-4362 Updated Nov 14

What to watch

GB-4362 is an early-stage, non-core program and is unlikely to drive meaningful stock movement in GENB until the company announces first-patient-dosed confirmation or initial safety data. Investors should focus on Generate's lead catalyst: Phase 3 SOLAIRIA-1 and SOLAIRIA-2 topline readouts for GB-0895 in severe asthma, which are the real value drivers for the stock.

Bull case
  • GB-4362 addresses a clear unmet need: mitigating toxicities from MMAE-based ADCs, a widely used cancer drug class, and could become a standard supportive-care adjunct if proven safe and effective.
  • The program received FDA Fast Track designation, which can accelerate development timelines and enable more frequent FDA interaction.
Bear case
  • GB-4362 is a very early-stage (preclinical/Phase 1) program with no published clinical data as of November 2026; most early-stage biotech assets fail before reaching approval.
  • The drug is a small, non-core program relative to Generate Biomedicines' lead asset GB-0895 (anti-TSLP in Phase 3 asthma), which drives the vast majority of the company's valuation. GB-4362 gets little to no mention in recent company updates.
  • No ClinicalTrials.gov record found, and the company has not disclosed whether patient dosing has begun, raising uncertainty about execution timelines.